Skip to main content
. 2015 Jun 25;6(27):23523–23532. doi: 10.18632/oncotarget.4395

Figure 3. tTF-pHLIP treatment induces thrombosis within tumor vessels, and tumor vessel accumulation of tTF-pHLIP.

Figure 3

A. MDA-MB-231 human breast cancer-bearing nude mice were injected with tTF-pHLIP or saline via a tail vein and the tumors were resected 8 hours post-injection. The tumors of mice treated with tTF-pHLIP were bruised and blackened (top left) in contrast to the vital appearance of the tumors in mice treated with saline (bottom left), indicating blood pooling due to vascular disruption. Tumor sections were subjected to hematoxylin and eosin (H&E) staining to detect thrombosis (middle, arrow). Immunostaining of tumor sections with anti-mouse platelet CD41 antibody further confirmed thrombosis in the tumors of tTF-pHLIP-treated mice (top right, darker brown). Data are representative of at least three separate experiments. B. FAM-labeled tTF-pHLIP was injected intravenously into nude mice bearing MDA-MB-231 tumors. Tumors were harvested 8 hours later, and tumor sections were stained with anti-CD34 antibody and examined by confocal microscopy. The tTF-pHLIP was green; blood vessels were visualized with anti-CD34 (brown); nuclei were stained with DAPI (blue).